SAB Biotherapeutics, Inc.
SABS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001833214
No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 87 institutions reported holding it in 13F filings for Q2 2026, worth $266.8M in total; no superinvestor holds it.
Other share classesSABSW
Q4 2024 vs. Q3 2024
How the institutions holding SAB Biotherapeutics, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 25 | 25 | 0 |
| Shares | 3.14M | 2.63M | −508.6K (−16.2%) |
| Value | $8.48M | $10.1M | +$1.63M (+19.3%) |
New holders (5)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Diadema Partners LP | 30,000 | $113.8K | 0.13% |
| Northern Trust Corp | 11,387 | $43.2K | 0.00% |
| UBS Group AG | 1,083 | $4.11K | 0.00% |
| Federation des caisses Desjardins du Quebec | 250 | $949 | 0.00% |
| MAI Capital Management | 130 | $494 | 0.00% |
Sold out (5)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| RTW Investments, LP | 635,276 | $1.72M |
| First Manhattan Co | 24,577 | $66.4K |
| Citadel Advisors LLC | 10,305 | $27.8K |
| Princeton Global Asset Management LLC | 500 | $1.35K |
| Barclays PLC | 10 | $27 |